1. Adelaide Research & Scholarship

Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 35 (Search time: 0.002 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2014Achieving the deep molecular response levels required for an imatinib discontinuation trial is strongly associated with the BCR-ABL level at the first qualifying timepointBranford, S.; Ross, D.; Yeung, D.; Braley, J.; Hughes, T.; 56th ASH Annual Meeting (6 Dec 2014 - 9 Dec 2014 : San Francisco, California)
2010Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDELL-II trialYeung, D.; Osborn, M.; White, D.; Branford, S.; Haswell, L.; Slader, C.; Issa, S.; Hiwase, D.; Hertzberg, M.; Schwarer, A.; Filshie, R.; Arthur, C.; Kwan, Y.; Forsyth, C.; Ross, D.; Mills, A.; Grigg, A.; Hughes, T.; Annual Meeting of the American Society of Hematology (52nd : 2010 : Orlando, Fl.)
2010Mutation analysis of BCR-ABL tyrosine kinase domain in new chronic phase-chronic myeloid leukemia patients with suboptimal response or treatment failure from imatinib treatmentKim, D.; Kim, D.; Kim, S.; Goh, H.; Pane, F.; Hughes, T.; Radich, J.; Lin, P.; Saglio, G.; Branford, S.; Martinelli, G.; Soverini, S.; Hochhaus, A.; American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2010A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be AppropriateBranford, S.; Goh, H.; Izzo, B.; Beppu, L.; Ortmann, C.; Duniec, K.; Jin, Y.; Woodman, R.; Pane, F.; Kim, D.; Radich, J.; Hughes, T.; American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2010Detection of low level nilotinib or dasatinib resistant BCR-ABL mutations by mass spectrometry in CML patients who fail Imatinib is highly predivtive of their subsequent clonal expansion when treated with the drug for which their mutation confers resistanceParker, W.; Ho, M.; Lawrence, R.; Irwin, D.; Scott, H.; Hughes, T.; Branford, S.; American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2010Towards DNA-based monitoring of therapy in chronic myeloid leukemiaMorley, A.; Bartley, P.; Ross, D.; Latham, S.; Budgen, B.; Branford, S.; Hughes, T.; American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2010Contrasting response of patients with chronic myeloid leukaemia (CML) and the highly imatinib resistant L248V mutation that may be related to an increased propensity of some patients to form an associated deletion mutant with increased imatinib sensitivityPrime, H.; Romeo, G.; Phillis, S.; Field, C.; Jamison, B.; Prime, J.; Parker, W.; Joske, D.; Hughes, T.; Branford, S.; Haematology Association of Australasia Annual Meeting (2010 : Auckland, New Zealand)
2010Limiting the variability within a BCR-ABL quantitative PCR (RQ-PCR) assay is essential for optimal concordance of results between laboratories generating BCR-ABL values on an international reporting scaleFletcher, L.; Prime, J.; Phillis, S.; Jamison, B.; Field, C.; Prime, H.; Sullivan, B.; Yeoman, A.; Georgievski, J.; Parker, W.; Slader, C.; Hughes, T.; Branford, S.; Haematology Association of Australasia Annual Meeting (2010 : Auckland, New Zealand)
2014The adverse effect of high sokal risk for first line imatinib treated patients is overcome by a rapid rate of BCR-ABL decline measured as early as 1 month of treatmentBranford, S.; Yeung, D.; Ross, D.; Parker, W.; Braley, J.; Seymour, J.; Hughes, T.; 56th ASH Annual Meeting (6 Dec 2014 - 9 Dec 2014 : San Francisco, California)
2013PCR-mediated recombination can lead to artificial chimera formation, which may pose as BCR-ABL1 compound mutationsParker, W.; Phillis, S.; Yeung, D.; Hughes, T.; Scott, H.; Branford, S.; 55th American Society of Hematology Annual Meeting and Exhibition (7 Dec 2013 - 10 Dec 2013 : New Orleans, Louisiana)

Discover